These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models. Chen C; Wicha SG; de Knegt GJ; Ortega F; Alameda L; Sousa V; de Steenwinkel JEM; Simonsson USH CPT Pharmacometrics Syst Pharmacol; 2017 Nov; 6(11):787-797. PubMed ID: 28657202 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536 [TBL] [Abstract][Full Text] [Related]
5. In silico evaluation and exploration of antibiotic tuberculosis treatment regimens. Pienaar E; Dartois V; Linderman JJ; Kirschner DE BMC Syst Biol; 2015 Nov; 9():79. PubMed ID: 26578235 [TBL] [Abstract][Full Text] [Related]
6. Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis. Mitchison DA Am J Respir Crit Care Med; 2003 May; 167(10):1298-9. PubMed ID: 12738593 [No Abstract] [Full Text] [Related]
7. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. Dutt M; Khuller GK J Antimicrob Chemother; 2001 Jun; 47(6):829-35. PubMed ID: 11389115 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Deol P; Khuller GK; Joshi K Antimicrob Agents Chemother; 1997 Jun; 41(6):1211-4. PubMed ID: 9174172 [TBL] [Abstract][Full Text] [Related]
9. A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations. Clewe O; Wicha SG; de Vogel CP; de Steenwinkel JEM; Simonsson USH J Antimicrob Chemother; 2018 Feb; 73(2):437-447. PubMed ID: 29136155 [TBL] [Abstract][Full Text] [Related]
10. Comparisons of Analysis Methods for Assessment of Pharmacodynamic Interactions Including Design Recommendations. Chen C; Wicha SG; Nordgren R; Simonsson USH AAPS J; 2018 Jun; 20(4):77. PubMed ID: 29931471 [TBL] [Abstract][Full Text] [Related]
11. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886 [TBL] [Abstract][Full Text] [Related]
13. Completing tuberculosis prophylaxis in jail: targeting treatment and a comparison of rifampin/pyrazinamide with isoniazid regimens. Lambert LA; Ijaz K; Navin TR Int J Tuberc Lung Dis; 2005 Feb; 9(2):230; author reply 230-1. PubMed ID: 15732748 [No Abstract] [Full Text] [Related]
14. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products. Singh S; Mohan B Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847 [TBL] [Abstract][Full Text] [Related]
15. Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India. Aruldhas BW; Hoglund RM; Ranjalkar J; Tarning J; Mathew SK; Verghese VP; Bose A; Mathew BS Br J Clin Pharmacol; 2019 Mar; 85(3):644-654. PubMed ID: 30588647 [TBL] [Abstract][Full Text] [Related]
16. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Gosling RD; Uiso LO; Sam NE; Bongard E; Kanduma EG; Nyindo M; Morris RW; Gillespie SH Am J Respir Crit Care Med; 2003 Dec; 168(11):1342-5. PubMed ID: 12917230 [TBL] [Abstract][Full Text] [Related]
17. Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients. Sturkenboom MG; Akkerman OW; van Altena R; de Lange WC; Kosterink JG; van der Werf TS; Alffenaar JC Eur Respir J; 2016 Oct; 48(4):1237-1239. PubMed ID: 27492836 [No Abstract] [Full Text] [Related]
18. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Labana S; Pandey R; Sharma S; Khuller GK Int J Antimicrob Agents; 2002 Oct; 20(4):301-4. PubMed ID: 12385689 [TBL] [Abstract][Full Text] [Related]
19. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361 [TBL] [Abstract][Full Text] [Related]
20. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Tasneen R; Tyagi S; Williams K; Grosset J; Nuermberger E Antimicrob Agents Chemother; 2008 Oct; 52(10):3664-8. PubMed ID: 18694943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]